825 INDUSTRIAL ROAD, SAN CARLOS, CA
Corporate Overview October 2026
Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Investor Presentation
Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
Corporate Overview June 2026
Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
Annual Report to Security Holders
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence